The study evaluated the company’s experimental drug, datopotamab deruxtecan (Dato-Dxd), as a second-line treatment for patients with non-small cell lung cancer (NSCLC). Analysts from BofA ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

Merck MRK announced that a phase II/III study has been initiated on its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in patients with platinum-resistant ovarian cancer.

hoping to build on the success of a partnership that already spawned a blockbuster drug. The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade ...

Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the topoisomerase I inhibitor DXd through a ...